BRPI9710363B1 - partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso. - Google Patents

partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.

Info

Publication number
BRPI9710363B1
BRPI9710363B1 BRPI9710363-2A BRPI9710363A BRPI9710363B1 BR PI9710363 B1 BRPI9710363 B1 BR PI9710363B1 BR PI9710363 A BRPI9710363 A BR PI9710363A BR PI9710363 B1 BRPI9710363 B1 BR PI9710363B1
Authority
BR
Brazil
Prior art keywords
rsv
respiratory syncytial
syncytial virus
recombinant respiratory
attenuated
Prior art date
Application number
BRPI9710363-2A
Other languages
English (en)
Inventor
Brian R Murphy
Peter L Collins
Stephen S Whitehead
Alexander A Bukreyev
Katalin Juhasz
Michael N Teng
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of BRPI9710363A publication Critical patent/BRPI9710363A/pt
Publication of BRPI9710363B1 publication Critical patent/BRPI9710363B1/pt
Publication of BRPI9710363B8 publication Critical patent/BRPI9710363B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI9710363 1996-07-15 1997-07-15 partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso. BRPI9710363B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2177396P 1996-07-15 1996-07-15
US4614197P 1997-05-09 1997-05-09
US4763497P 1997-05-23 1997-05-23
PCT/US1997/012269 WO1998002530A1 (en) 1996-07-15 1997-07-15 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Publications (3)

Publication Number Publication Date
BRPI9710363A BRPI9710363A (pt) 2000-01-11
BRPI9710363B1 true BRPI9710363B1 (pt) 2011-11-16
BRPI9710363B8 BRPI9710363B8 (pt) 2021-07-06

Family

ID=27361727

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9710363-2A BR9710363A (pt) 1996-07-15 1997-07-15 "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
BRPI9710363 BRPI9710363B8 (pt) 1996-07-15 1997-07-15 partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9710363-2A BR9710363A (pt) 1996-07-15 1997-07-15 "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"

Country Status (12)

Country Link
US (2) US5993824A (pt)
EP (2) EP0912724B1 (pt)
JP (2) JP4413999B2 (pt)
KR (2) KR100658491B1 (pt)
CN (1) CN101012454B (pt)
AT (1) ATE451451T1 (pt)
AU (1) AU3799797A (pt)
BR (2) BR9710363A (pt)
CA (1) CA2257823A1 (pt)
DE (1) DE69739689D1 (pt)
ES (1) ES2345643T3 (pt)
WO (1) WO1998002530A1 (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
WO1998050529A1 (en) * 1997-05-02 1998-11-12 The Uab Research Foundation Attenuation of negative stranded rna viruses by rearrangement of their genes and uses thereof
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) * 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
EP1015594A1 (en) * 1997-09-19 2000-07-05 American Cyanamid Company Attenuated respiratory syncytial viruses
US20100028377A1 (en) * 1997-09-26 2010-02-04 Medimmune, Llc Recombinant RSV Virus Expression Systems And Vaccines
AU2006200619B2 (en) * 1997-09-26 2007-12-13 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
IL140265A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Methods and interferon deficient substrates for propagation of viruses
DK1098961T3 (da) 1998-06-12 2008-05-26 Andrej Y Dr Egorov Gensplejsede svækkede vira, der inducerer interferon
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
AU781238B2 (en) * 1999-04-13 2005-05-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
IL145796A0 (en) 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
CA2378661A1 (en) 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
ATE419369T1 (de) * 1999-07-09 2009-01-15 Us Gov Health & Human Serv Chimäre mensch-rinder respiratory syncytial virus vakzinen
KR20020092889A (ko) * 1999-07-13 2002-12-12 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 면역조절분자를 발현시키는 호흡기 신시티움 바이러스
ES2288866T3 (es) * 1999-09-06 2008-02-01 Dnavec Research, Inc. Paramixovirus que contienen una secuencia de inicio de la transcripcion modificada.
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) * 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
DE60139319D1 (en) 2000-06-23 2009-09-03 Intervet Int Bv Us
BRPI0112276B8 (pt) * 2000-06-23 2021-05-25 The Government Of The Us Secretary Of Department Of Health And Human Services vírus sincicial respiratório (rsv) recombinante infeccioso e polinucleotídeo isolado contendo um genoma ou antigenoma de resv recombinante parcial ou completo
WO2002030457A2 (en) * 2000-10-12 2002-04-18 Washington University In St. Louis Microbes having an attenuating mutation comprising a transcription terminator
PT1480671E (pt) * 2000-11-28 2007-11-20 Medimmune Vaccines Inc Sistemas de expressão de vírus rsv recombinante e vacinas
JP5503096B2 (ja) 2001-01-19 2014-05-28 ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ 感受性哺乳動物において気道疾患を引き起こすウイルス
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
UA82466C2 (uk) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
EP1438399A4 (en) * 2001-09-28 2005-09-14 Univ North Carolina PARAMYXOVIRUSES AS GENE TRANSFER VECTORS TO PULMONARY CELLS
AU2002364121C1 (en) 2001-11-21 2010-02-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 1 (HPIVI) from cDNA
CA2477235A1 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN1678345A (zh) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
WO2004027037A2 (en) 2002-09-18 2004-04-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services RECOVERY OF RECOMBINANT HUMAN PARAINFLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS TO ELICIT IMMUNE RESPONSES AGAINST PIV AND OTHER HUMAN PATHOGENS
WO2004041838A1 (en) * 2002-11-01 2004-05-21 University Of Massachusetts Regulation of transcription elongation factors
WO2005014626A2 (en) 2003-02-28 2005-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
BRPI0410702B1 (pt) 2003-05-28 2022-04-12 Wisconsin Alumni Research Foundation Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus
CN1871355B (zh) 2003-06-09 2011-12-14 惠氏 从cDNA中回收非节段性负链RNA病毒的改进方法
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
NZ548107A (en) 2003-12-24 2009-09-25 Nederlanden Staat A respiratory syncytial virus with a genomic deficiency complemented in trans
ES2393492T3 (es) 2004-05-25 2012-12-21 Medimmune, Llc Variantes de hemaglutinina y neuraminidasa de influenza
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
AU2005314446A1 (en) * 2004-11-16 2006-06-15 Janssen Pharmaceutica N.V. Sphingosine kinase-1 mediates gene expression regulation of a monocyte chemoattractant protein-1 gene
JP2008520248A (ja) 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
CA2600730C (en) 2005-03-08 2014-11-25 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
BRPI0612268A2 (pt) 2005-06-21 2009-01-27 Medimmune Vaccines Inc Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
WO2007126810A2 (en) 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN104278014A (zh) 2006-08-09 2015-01-14 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
EP4368202A3 (en) 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2674486A1 (en) 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
US20110189232A1 (en) * 2008-07-01 2011-08-04 The Government Of The United States Of America Represented By The Secretary RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
RU2011122653A (ru) 2008-11-05 2012-12-20 Асахи Гласс Компани, Лимитед Фторированный эластичный сополимер, способ его получения и сшитый каучук
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2396033B1 (en) 2009-02-12 2016-09-28 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
WO2011014645A1 (en) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US8597637B1 (en) 2010-05-18 2013-12-03 Weidong Zhang Breast cancer therapy using an engineered respiratory syncytial virus
US9044499B1 (en) 2010-06-22 2015-06-02 Weidong Zhang NS1/2-deficient respiratory syncytial virus and melanoma treatment
CA2849434A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
MX369469B (es) * 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
CN103789276B (zh) * 2014-01-14 2015-12-09 昆明理工大学 一种呼吸道合胞病毒减毒毒株及其应用
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
US10541367B2 (en) * 2014-04-10 2020-01-21 Joled Inc. Organic EL display panel production method
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
CN107250353B (zh) 2015-02-26 2021-07-23 勃林格殷格翰动物保健有限公司 二价猪流感病毒疫苗
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
CA2995382A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
KR20180085730A (ko) 2015-10-29 2018-07-27 에모리 유니버시티 키메라 rsv, 면역원성 조성물, 및 사용 방법
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CN109414488A (zh) 2016-06-03 2019-03-01 罗切斯特大学 马流感病毒减毒活疫苗
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107384958B (zh) * 2017-07-14 2020-04-10 北京交通大学 基于反向遗传学构建的rsv反基因组质粒及其应用
BR112020017354A2 (pt) 2018-02-27 2020-12-15 University Of Rochester Composição imunológica multivalente, e, método para induzir uma resposta imune contra uma pluralidade de vírus da influenza equina.
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
US20220133877A1 (en) 2019-02-27 2022-05-05 University Of Rochester Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US20030054505A1 (en) 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
AU712213B2 (en) 1995-09-22 1999-11-04 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
AU727923B2 (en) * 1995-09-27 2001-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
BR9710363A (pt) * 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
US6699476B1 (en) * 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
AU7797798A (en) 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
EP1012244B1 (en) 1997-07-11 2007-05-09 Yale University Rhabdoviruses with reengineered coats
US6364957B1 (en) * 1997-10-09 2002-04-02 Applied Materials, Inc. Support assembly with thermal expansion compensation
WO1999024564A1 (en) 1997-11-10 1999-05-20 University Of Maryland PRODUCTION OF NOVEL BOVINE RESPIRATORY SYNCYTIAL VIRUSES FROM cDNAs
AU781238B2 (en) 1999-04-13 2005-05-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
IL145796A0 (en) 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
WO2001004321A1 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of m2 orf2
KR20020092889A (ko) 1999-07-13 2002-12-12 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 면역조절분자를 발현시키는 호흡기 신시티움 바이러스
US9615524B2 (en) 2015-04-17 2017-04-11 Pop Vriend Research Bv Garden bean variety PV-832

Also Published As

Publication number Publication date
EP0912724A1 (en) 1999-05-06
EP2112220A2 (en) 2009-10-28
CA2257823A1 (en) 1998-01-22
US7709007B2 (en) 2010-05-04
ES2345643T3 (es) 2010-09-28
CN101012454A (zh) 2007-08-08
BRPI9710363B8 (pt) 2021-07-06
KR100658491B1 (ko) 2006-12-18
BR9710363A (pt) 2000-01-11
AU3799797A (en) 1998-02-09
US20060159703A1 (en) 2006-07-20
ATE451451T1 (de) 2009-12-15
KR100894670B1 (ko) 2009-04-22
BRPI9710363A (pt) 2000-01-11
EP0912724B1 (en) 2009-12-09
JP2008283984A (ja) 2008-11-27
KR20000023802A (ko) 2000-04-25
WO1998002530A1 (en) 1998-01-22
DE69739689D1 (de) 2010-01-21
EP2112220A3 (en) 2010-01-06
JP4413999B2 (ja) 2010-02-10
US5993824A (en) 1999-11-30
KR20060015658A (ko) 2006-02-17
CN101012454B (zh) 2011-11-16
JP2002511731A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
BRPI9710363B1 (pt) partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
DE69325370D1 (de) Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
Scott et al. IL-12 as an adjuvant for cell-mediated immunity
WO2000061611A3 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
FR2742756B1 (fr) Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
CA2385655A1 (en) Dna immunization against chlamydia infection
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
MXPA02004627A (es) Vacunas contra el micoplasma bovis y sus metodos de uso.
Gutiérrez-Álvarez et al. Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice
CA2533877A1 (en) Safe mutant viral vaccines
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
EP1323428A3 (en) Avirulent Salmonella typhi microbes and uses thereof
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
TR200002974T2 (tr) Bruselloza karşı canlı aşı
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
WO2000045840A8 (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
WO2003049670A3 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
BR0002602A (pt) Vacina viva atenuada, uso de uma bactéria viva atenuada, e, processo para a preparação de uma vacina
CA2342305A1 (en) Pestivirus mutants and vaccines containing the same